The House Appropriations Committee directed the FDA to reform how it signs off on new INDs, citing the need for the U.S. to keep pace with China and other countries developing therapies. The push comes as concerns persist that regulatory timelines can lag against the speed of global clinical execution. Separately, the FDA fielded sharp criticism over its Commissioner’s National Priority Voucher (CNPV) pilot during a June 4 listening session. Industry and patient groups urged the agency to pause or bring the program through normal public feedback and transparency processes, while supporters pointed to the accelerated reviews already enabled under the pilot. Taken together, the actions highlight heightened scrutiny of how ultra-fast pathways are set up, governed, and evaluated—particularly for programs tied to national priorities. For biotech teams, this increases the importance of regulatory strategy planning that anticipates both faster decision gates and tighter expectations around process integrity.